Showing 2991-3000 of 4063 results for "".
- RVL Pharmaceuticals Upneeq Wins 2021 MedTech Breakthrough Awardhttps://modernod.com/news/rvl-pharmaceuticals-upneeq-wins-2021-medtech-breakthrough-award/2479196/RVL Pharmaceuticals, a subsidiary of Osmotica Pharmaceuticals, announced that its ptosis drug Upneeq (oxymetazoline hydrochloride ophthalmic solution), 0.1% has been selected as the winner of the “Best New Technology Solution for Drug Delivery” award in the fifth annual MedTech Breakthrough Award
- Zeiss Celebrates 175th Anniversary in 2021https://modernod.com/news/zeiss-celebrates-175th-anniversary-in-2021/2479194/Zeiss’ success story began 175 years ago, in a small workshop. On November 17, 1846, young mechanic Carl Zeiss opened his workshop for precision mechanics and optics in Jena, thus laying the foundation for what would become today’s global technology player Zeiss. Zeiss went on to join
- Alcon Presents Highlights of ARVO 2021 Datahttps://modernod.com/news/alcon-presents-highlights-of-arvo-2021-data/2479149/Alcon will be presenting new data at the Association for Research in Vision and Ophthalmology (ARVO) Virtual Meeting (May 1-7). Presentations include data for the Systane iLux MGD Thermal Pulsation System, Precision1 daily disposable contact lenses, and a forthcoming reusable monthly contact lens
- Bausch + Lomb Will Present New Scientific Data And Analyses On Products And Pipeline Programs During ARVO 2021https://modernod.com/news/bausch-lomb-will-present-new-scientific-data-and-analyses-on-products-and-pipeline-programs-during-arvo-2021/2479139/Bausch + Lomb announced the presentation of new scientific data and clinical analyses, including one podium presentation and 11 poster presentations, during the virtual Association for Research in Vision and Ophthalmology (ARVO) annual meeting, which will take place from Ma
- Aerie Pharmaceuticals Announces Presentations at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meetinghttps://modernod.com/news/aerie-pharmaceuticals-announces-presentations-at-the-2021-association-for-research-in-vision-and-ophthalmology-arvo-annual-meeting/2479128/Aerie Pharmaceuticals, an ophthalmic pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases, and retinal diseases, announced it will participate and have poster
- More than 200 Exhibiting Companies Commit to Vision Expo East 2021https://modernod.com/news/more-than-200-exhibiting-companies-commit-to-vision-expo-east-2021/2479110/
- Study: Glaucoma May Be More than Just an Issue of Eye Pressurehttps://modernod.com/news/study-glaucoma-may-be-more-than-just-an-issue-of-eye-pressure/2479078/A chemical known to protect nerve cells also slows glaucoma, the leading cause of irreversible blindness, results of a new study in rats show. Led by researchers at NYU Grossman School of Medicine, the study centers on the watery fluid inside the eye on which its function depends. Fluid pr
- National Optometric Association to Host Regional Meeting at Vision Expo East 2021https://modernod.com/news/national-optometric-association-to-host-regional-meeting-at-vision-expo-east-2021/2479076/The Vision Council and Reed Exhibitions, organizers of Vision Expo, announce that the National Optometric Association (NOA), an organization dedicated to advancing the visual health of minority populations through the delivery of effective and efficient eye and vision ca
- MediPrint Ophthalmics Announces Completion of SIGHT-1 Phase 2a Clinical Studyhttps://modernod.com/news/mediprint-ophthalmics-announces-successful-completion-of-its-sight-1-phase-2a-clinical-study/2478983/MediPrint Ophthalmics announced the successful completion of the first study in its SIGHT (Sustained Innovative Glaucoma and ocular Hypertension Treatme
- Single Dose of Pfizer, BioNTech’s COVID-19 Vaccine 85% Effective: Studyhttps://modernod.com/news/single-dose-of-pfizer-biontechs-covid-19-vaccine-85-effective-study/2478893/Study results published in The Lancet showed that a single dose of Pfizer and BioNTech’s COVID-19 vaccine BNT162b2 is 85% effective at preventing symptomatic disease 15 to 28 days after being administered. The data, which come from an analysis of healthcare workers in Israel, also